bioAffinity Technologies In the News
08 Enero 2024 - 7:00AM
Business Wire
Here is a summary of the latest news about bioAffinity
Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company
focused on the need for noninvasive tests for the detection of
early-stage cancer and lung disease.
bioAffinity Technologies (BIAF) and CyPath® Lung Featured on
Bloomberg TV, National Podcasts and Upcoming Webinar
bioAffinity Technologies’ President and CEO Maria Zannes was
recently featured on “Small Stocks, Big Money™” on Bloomberg TV.
Craig Brelsford with RedChip Companies interviewed Maria about
bioAffinity Technologies’ advancements in the medical field,
including commercialization of CyPath® Lung, a noninvasive test for
the early detection of lung cancer. If you missed the show, you can
find it on YouTube. Maria also was interviewed for the RedChip
podcast available on its website. Learn more about bioAffinity
Technologies by registering for the RedChip webinar with Maria to
take place via Zoom on Tuesday, Jan. 9, at 4:15 p.m. ET.
Medicare Reimbursement for CyPath Lung Effective Jan.
1
On Monday, Jan. 1, 2024, Medicare’s payment determination for
CyPath® Lung became effective. The American Medical Association
issued the Current Procedural Terminology (CPT) code 0406U for
CyPath® Lung last June, and the Centers for Medicare and Medicaid
Services (CMS) accepted the Medicare Advisory Panel on Clinical
Diagnostic Laboratory Tests’ recommendation for payment. The
Medicare payment also serves as a reference for private payers. Our
wholly owned subsidiary, Precision Pathology Laboratory Services,
has set a price of $1,900 for CyPath® Lung. CMS’ 2024 clinical
laboratory fee schedule reflects the rapid pace of innovation in
medical science and health technology and is designed to ensure
accurate coding and reporting of medical procedures and
services.
bioAffinity Technologies Partners with the American Cancer
Society to Increase Lung Cancer Screening
“The Power of Three”
bioAffinity Technologies joined the American Cancer Society and
University of Texas Health San Antonio to raise awareness and
funding for lung cancer screening, showing that when we work
together, lung cancer screening programs are a success. There is
still time to contribute to this important program that has
increased lung cancer screening participation from 7% to 24% of
those eligible. What we learn here can be used to increase
screening in your hometown. Please DONATE to help save lives
through the early detection of lung cancer.
Ending 2023 with our Partners in the Fight Against Lung
Cancer
We ended the year participating in two important meetings. The
American Cancer Society’s National Lung Cancer Roundtable is the
premier event that brings clinicians, researchers, patients,
caregivers and industry together to transform outcomes for
individuals with lung cancer. As an NLCRT member, we were proud to
participate with both physicians who will order CyPath® Lung and
the patients who will benefit most from our test. We also focused
on our military veterans at a meeting of the National Association
of Veterans’ Research and Education Foundations (NAVREF) where we
met with Terri Tanielian, Special Assistant to the President for
Veterans Affairs, and Kit Teague, Executive Director of the
Veterans Health Administration Innovation Ecosystem. Both
organizations share our commitment to saving lives through early
detection when lung cancer treatment is most effective.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for
noninvasive diagnosis of early-stage cancer and diseases of the
lung and targeted cancer treatment. The Company’s first product,
CyPath® Lung, is a noninvasive test that has shown high sensitivity
and specificity for the detection of early-stage lung cancer.
CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by
Precision Pathology Laboratory Services, a subsidiary of
bioAffinity Technologies, Inc. Research and optimization of the
Company’s platform technologies are conducted in its laboratories
at Precision Pathology and The University of Texas at San Antonio.
For more information, visit www.bioaffinitytech.com and follow us
on LinkedIn and X (Twitter).
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. These forward-looking
statements are based upon current estimates and assumptions and
include statements regarding the need for noninvasive diagnosis of
early-stage cancer and diseases of the lung and targeted cancer
treatment. These forward-looking statements are subject to various
risks and uncertainties, many of which are difficult to predict
that could cause actual results to differ materially from current
expectations and assumptions from those set forth or implied by any
forward-looking statements. Important factors that could cause
actual results to differ materially from current expectations
include, among others, the ability for CyPath® Lung, to fill the
need for noninvasive diagnosis of early-stage cancer and diseases
of the lung and targeted cancer treatment and the other factors
discussed in the Company’s Annual Report on Form 10-K for the year
ended December 31, 2022, and its subsequent filings with the SEC,
including subsequent periodic reports on Forms 10-Q and 8-K. Such
forward-looking statements are based on facts and conditions as
they exist at the time such statements are made and predictions as
to future facts and conditions. While the Company believes these
forward-looking statements are reasonable, readers of this press
release are cautioned not to place undue reliance on any
forward-looking statements. The information in this release is
provided only as of the date of this release, and the Company does
not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240108702168/en/
bioAffinity Technologies Julie Anne Overton Director of
Communications jao@bioaffinitytech.com
Investor Relations Dave Gentry RedChip Companies Inc.
1-800-RED-CHIP (733-2447) Or 407-491-4498 BIAF@redchip.com
bioAffinity Technologies (NASDAQ:BIAF)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
bioAffinity Technologies (NASDAQ:BIAF)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024